BCD-272 is an originator monospecific non-neutralizing (non-effector) antibody (Immunoglobulin G1 (IgG1)).

A monoclonal antibody is a protein engineered by scientists in the laboratory, equivalent to the natural antibodies of the immune system, aimed at binding to a specific target site in the human body¹.

Asthma is a heterogeneous medical condition associated with chronic airway inflammation and respiratory symptoms that vary in timing and severity and present along with variable airflow obstruction².

BCD-272 is one of BIOCAD’s drug products under clinical development. The mechanism of action of the innovative drug is to reduce the activity of airway inflammation, which occurs in asthma. BCD-272 is expected to target one of the key proteins responsible for disease development by inhibiting the inflammatory process.

This website section includes information about an investigational medicinal product for human use.

1. Weiner L. M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.
2. Federal clinical guidelines for the diagnosis and management of asthma. Russian Respiratory Society. Moscow; 2021:7.